|
| |
4SC AG4SC is a drug discovery and development company that uses its cheminformatics-based technology platform for the discovery and development of new drug candidates for the treatment of patients suffering from diseases with high medical needs.
Thus, 4SC has been generating a risk-balanced and continuously advancing pipeline of projects. 4SC's therapeutic focus centres on cancer and inflammatory diseases since these indications combine significant market potential and high medical needs with reasonable development time and cost in the early clinical stages.
4SC's most advanced drug candidate for the treatment of autoimmune disorders SC12267, has successfully completed phase I studies. Preparations for phase IIa trials with rheumatoid arthritis patients are under way. Additional programmes in research and pre-clinical stages are progressing towards clinical development. All of 4SC's pipeline projects have been generated by 4SC's proprietary technology platform.
4SC aims to realise the commercial potential of these programmes through licensing arrangements with pharmaceutical partners.
| Contact Details: |
| Am Klopferspitz 19a |
| Martinsried |
| |
| 82152 |
| Germany |
| Tel: | 49 (0)89 700763-0 |
| Fax: | 49 (0)89 700763-29 |
| Email: | manfred.groeppel@4sc.com |
| WWW: | www.4sc.com/
|
| |
Recent Publications by 4SC AG: |  |
N-substituted 2'-(aminoaryl)benzothiazoles as kinase inhibitors: hit identification and scaffold hopping.
Starting with a hit from vHTS attained by a docking procedure of virtual... | 29th August, 2009
| 4SC AG, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany.
| Bioorg Med Chem Lett. 2009 Mar 1;19(5):1349-56. Epub 2009 Jan 22.
DOI Direct Link |
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
New structural classes of K(V)1.3 and IK-1 ion channel blockers have been... | 27th August, 2009
| 4SC AG, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany.
| Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304. Epub 2009 Feb 25.
DOI Direct Link |
Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization.
Based on an (aminoaryl)benzothiazole quinazoline hit structure for kinase... | 21st August, 2009
| 4SC AG, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany.
| Bioorg Med Chem. 2009 Sep 15;17(18):6728-37. Epub 2009 Jul 25.
DOI Direct Link |
Discovery of 5-HT6 receptor ligands based on virtual HTS.
Based on a pharmacophore alignment on a 5-HT(6) ligand applying 4SCan... | 24th June, 2008
| 4SC AG, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany.
| Bioorg Med Chem Lett. 2007 Nov 15;17(22):6224-9. Epub 2007 Sep 8.
DOI Direct Link |
Optimizing the signal-to-noise ratio of scoring functions for protein--ligand docking.
Empirical scoring functions provide estimates of the free energy of... | 5th June, 2008
| 4SC AG, Am Klopferspitz 19a, D-82152 Planegg-Martinsried, Germany.
| J Chem Inf Model. 2008 Mar;48(3):602-12. Epub 2008 Feb 23.
DOI Direct Link |
→View more 4SC AG research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 167 times since April 2007, the link to the organisation's website has been followed 26 times Search for more companies in Martinsried Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for 4SC AG |
